

JC06 Rec'd PCTD 10 AUG 2005 #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock et al	Filed: Herewith
Application No.: 10/539,486	Attorney Docket No.: 100855-1P US
PCT Application No.: PCT/GB03/05498	Examiner: Not yet assigned
Title: OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS	

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached form(s) PTO-1449. All of the cited references were listed on the International Search Report, a copy of which is enclosed herewith for the convenience of the Examiner. Copies of the references are not being provided herewith because it is believed they were previously forwarded to the USPTO by the International Patent Bureau. Applicants are also enclosing a copy of the International Examination Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,



Name: Heidi Berven
Dated: August 10, 2005
Reg. No.: 48,951
Phone No.: 1 781 839 4336

Enclosures: Form 1449
International Search Report
International Examination Report

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/539,486
Filing Date	June 17, 2005
First Named Inventor	Michael, Barry GRAVESTOCK
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100855-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US1	5 565 571		Barbachyn Michael R et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AA	WO 03/022824	March 20, 2003	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
	AB	WO 01/94342	December 13, 2004	Dong A Pharm. Co Ltd.		<input type="checkbox"/>
	AC	WO 00/29396	May 25, 2000	Bayer AG		<input type="checkbox"/>
	AD	WO 99/33839	July 8, 1999	Cheil Jedang Corporation		<input type="checkbox"/>
	AE	WO 98/54161	December 3, 1998	Pharmacia & UpJohn Company		<input type="checkbox"/>
	AF	WO 93/09103	May 13, 1993	The UpJohn Company		<input type="checkbox"/>
	AG	EP 0 352 781	January 31, 1990	E.I DU Pont De Nemours and Company		<input type="checkbox"/>
	AH	WO 99/03846	January 29, 1999	Bayer AG		<input type="checkbox"/>
	AI	WO 97/21708	June 19, 1997	Pharmacia & UpJohn Company		<input type="checkbox"/>
	AJ	WO 04/056816	July 8, 2004	AstraZeneca AB AstraZeneca UK Limited		
	AK	WO 04/056818	July 8, 2004	AstraZeneca AB AstraZeneca UK Limited		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/539,486
Filing Date	June 17, 2005
First Named Inventor	Michael, Barry GRAVESTOCK
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100855-1P US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	CHUNG-HO PARK ET AL : "ANTIBACTERIALS . SYNTHESIS AND STRUCTURE-ACTIVITY STUDIES OF 3-ARYL-2-OXOOAZOLIDINES . 4 MULTIPLY-SUBSTITUTED ARYL DERIVATIVES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY . WASHINGTON, US, vol . 35, no . 6, 20 March 1992 (1992-03-20), pages 1156-1165, XP000567006 ISSN : 0022-2623 page 1159, summary	<input type="checkbox"/>
	AB	PAE A N ET AL : "Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol . 9, no . 18, 20 September 1999 (1999-09-20), pages 2679-2684, XP004179951 ISSN : 0960-894X the whole document	<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2..